Pharmaceutical News

RSS

Study reveals that more than 14% of pregnant women are prescribed opioids for pain

More than 14 percent of pregnant women were prescribed opioids (narcotics) for pain at some time during their pregnancy, according to a study posted to the online version of Anesthesiology.

13 Feb 2014

LA BioMed researchers test investigational drug for treatment of Sanfilippo B syndrome

A promising new therapy has - for the first time - reduced damage to the brain that can be caused by Sanfilippo B (MPS IIIB), a rare and devastating genetic disease, Los Angeles Biomedical Research Institute researchers will report today in a presentation at the Lysosomal Disease Network's 10th Annual WORLD Symposium-.

12 Feb 2014

Scientists receive €85 million international drive to develop new and effective drugs

An increasing biological resistance to antibiotics treatment is to be countered by Aston University scientists who will lead a €85 million international drive to develop new and effective drugs.

12 Feb 2014

MIT develops robot that may speed up drug development for stroke patients

The development of drugs to treat acute stroke or aid in stroke recovery is a multibillion-dollar endeavor that only rarely pays off in the form of government-approved pharmaceuticals.

12 Feb 2014

Microbiologists find way to use statins to fight Hantavirus

wo Perelman School of Medicine microbiologists may have found a way to use statins, the well-known blockbuster cholesterol-lowering drugs, to fight the hantavirus, a mysterious and lethal microorganism that appeared suddenly in the US southwest over 20 years ago.

12 Feb 2014

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery."

12 Feb 2014

Scientists find neutralizing antibodies that protects humanized mice from HIV transmission

NIH-funded scientists have shown that boosting the production of certain broadly neutralizing antibodies can protect humanized mice from both intravenous and vaginal infection with HIV. Humanized mice have immune systems genetically modified to resemble those of humans, making it possible for them to become HIV-infected.

12 Feb 2014

FDA approves two drugs for long-term weight loss

Options are limited in America's battle of the bulge. While diet and exercise can help in the short term, they are frustratingly ineffective in the long run.

12 Feb 2014

IMF announces approval of POMALYST medication in Canada for patients with myeloma

The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - said POMALYST (pomalidomide) approval by Health Canada provides patients the most up-to-date oral therapy available for patients who have exhausted all other treatments.

11 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Tamoxifen drug appears to kill fungus associated with deadly brain infection

The drug tamoxifen appears to kill a fungus associated with a deadly brain infection that afflicts HIV/AIDS patients, according to a University of Rochester study published online today by mBio, the journal of the American Society for Microbiology.

11 Feb 2014

Cardiome Pharma's subsidiary signs agreement with Tamro to distribute BRINAVESS in Sweden

Cardiome Pharma Corp. today announced that its subsidiary, Correvio GmbH, has entered into an agreement with Tamro AB, headquartered in Gothenburg, Sweden, to distribute BRINAVESS (vernakalant IV) to customers in the Swedish market.

11 Feb 2014

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.

11 Feb 2014

Drug used for treating breast cancer also kills fungal disease

Tamoxifen, a drug currently used to treat breast cancer, also kills a fungus that causes a deadly brain infection in immunocompromised patients. The findings, which could lead to new treatments for a disease that kills more HIV/AIDS patients than tuberculosis, appear in mBio-, the online open-access journal of the American Society for Microbiology (ASM.)

11 Feb 2014

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.

10 Feb 2014

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN for use within the National Health Service Scotland under a simple patient access scheme.

10 Feb 2014

Merck, Samsung Bioepis agree to develop, commercialize MK-1293 for treatment of diabetes

Merck, known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon.

10 Feb 2014

Mallinckrodt announces commercial launch of PENNSAID

Mallinckrodt today announced the commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the treatment of the pain of osteoarthritis of the knees.

10 Feb 2014

New study analyses risk factors and mortality among heroin, cocaine consumers admitted to treatment

A new study analyses the risk factors and excess mortality among heroin and cocaine consumers admitted to treatment in Spain. The results reveal that the fatality rate among consumers of both drugs is 14.3 times higher than for the general population, while among those only using cocaine, it is 5.1 times higher.

10 Feb 2014

New method to build tiny degradable 'medicine factories' inside the body

A factory built of gel does not sound very durable. But the new type of micro-factories invented by researchers at Aarhus University do not have to last.

9 Feb 2014

Pharmaceutical News

Study reveals that more than 14% of pregnant women are prescribed opioids for pain

LA BioMed researchers test investigational drug for treatment of Sanfilippo B syndrome

Scientists receive €85 million international drive to develop new and effective drugs

MIT develops robot that may speed up drug development for stroke patients

Microbiologists find way to use statins to fight Hantavirus

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Scientists find neutralizing antibodies that protects humanized mice from HIV transmission

FDA approves two drugs for long-term weight loss

IMF announces approval of POMALYST medication in Canada for patients with myeloma

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Tamoxifen drug appears to kill fungus associated with deadly brain infection

Cardiome Pharma's subsidiary signs agreement with Tamro to distribute BRINAVESS in Sweden

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

Drug used for treating breast cancer also kills fungal disease

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

Merck, Samsung Bioepis agree to develop, commercialize MK-1293 for treatment of diabetes

Mallinckrodt announces commercial launch of PENNSAID

New study analyses risk factors and mortality among heroin, cocaine consumers admitted to treatment

New method to build tiny degradable 'medicine factories' inside the body

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News